secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001682852-25-000006
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q4 net loss $1.1B, EPS $(2.91); FY2024 revenue $3.2B falls 53%; guides 2025 rev $1.5-2.5B
--------------------------------------------------------------------------------

- Q4 revenue $1.0B (-66% YoY); GAAP net loss $1.1B vs net income $217M in Q4 2023.
- FY2024 revenue $3.2B (-53% YoY); GAAP net loss $3.6B; EPS $(9.28).
- FY2024 cost of sales 47% of net product sales, including $238M non-cash charge for manufacturing agreement termination.
- 2025 revenue guided $1.5-2.5B; expects first-half 2025 revenue only ~$0.2B due to seasonality.
- Filed three BLAs: next-gen COVID (PDUFA May 31), RSV for 18-59 (PDUFA June 12), flu/COVID combo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285225000006/0001682852-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285225000006/mrna-20250214.htm
  HTML page:      https://secwatch.observer/filing/0001682852-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer